A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01749410|
Recruitment Status : Completed
First Posted : December 13, 2012
Results First Posted : September 10, 2015
Last Update Posted : September 10, 2015
|Condition or disease||Intervention/treatment|
|Chronic Migraine, Headaches||Biological: onabotulinumtoxinA|
|Study Type :||Observational|
|Actual Enrollment :||33 participants|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2014|
Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
Previous treatment with onabotulinumtoxinA for Chronic Migraine.
- Change From Baseline in the Number of Headache Days [ Time Frame: Treatment Cycle 7 (approximately 1.5 years) ]The mean number of headache days was counted as the number of headache days occurring during the 30 day period ending with treatment cycle 7. Each treatment cycle was administered approximately every 12 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01749410
|United States, California|
|Encinitas, California, United States|
|Study Director:||Medical Director||Allergan|